Market Overview

UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform

Share:
Related REGN
Regeneron Rapid Response Platform for Emerging Infectious Diseases Described in Proceedings of the National Academy of Sciences Publication
Jim Cramer Advises His Viewers On GlaxoSmithKline, American International Group, Caesars And Caesars Acquisition
Is Avalanche Biotechnologies A Good Buy Now After Phase 2 Results For Its Wet AMD Drug? (Seeking Alpha)

Credit Suisse initiales coverage on Regeneron Pharmaceutical (NASDAQ: REGN) with an Outperform rating and a $187 price target.

Credit Suisse said, "The primary value driver remains quarterly sales of Eylea. Proposed legislation regulating compounding pharmacies, a permanent J code in January and the launch in RVO could all help boost sales. Competitor data for Amgen's AMG145 (anti-PCSK9) and Ophthotech's Fovista have all recently been disclosed, and key clinical data for Regeneron are limited in the near term."

Regeneron Pharmaceutical closed at $144.90 on Monday.

Latest Ratings for REGN

DateFirmActionFromTo
Jun 2015RBC CapitalReiteratesOutperform
Jun 2015BairdMaintainsOutperform
May 2015CitigroupMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (REGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters